Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Inclusion Criteria: * Age \> 18 yo. * Primary pigmented or amelanotic choroidal melanoma measurement of 16 mm or less in the largest vessel diameter and 6 mm or less in the apical height. * Location of the tumor posterior to the equator. * Documented growth by A/B scan. * Risk factor for metastasis (thickness greater than 2 mm, symptoms, tumor margin at the optic disc) * Ability to provide inform consent. * Comply with the study assessment for the cooperation of the study. Exclusion Criteria: * Pregnancy or lactation. * Premenopausal women not using adequate contraception; surgical sterilization or use of oral contraception, barrier contraception with either a condom or diaphragm or in conjunction with spermicidal gel, an IUD or contraceptive hormon implant or patch. * Current infection or inflammation in either eye. * Extension of tumor into the orbit. * Retinal spread or metastatic disease. * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. * Any known allergy to any of the components to be used in the study. * Participation in another simultaneous medical investigation or trial.